TriHeal-80

Manufacturer
ForReal Pharmaceuticals
Effective date
2021-08-12
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
3
Source
legacy-cache
Hydrated at
2026-08-01 22:38:26

Label at a glance#

ProductTriHeal-80
Active ingredientTRIAMCINOLONE ACETONIDE, DIMETHICONE
Label structure4 sections

Label contents#

Full prescribing information#

Triamcinolone Acetonide Cream USP (0.1%)

SPL UNCLASSIFIED SECTION

DESCRIPTION

DESCRIPTION SECTION

The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. Triamcinolone acetonide is a member of this class. Chemically triamcinolone acetonide is pregna-1, 4-diene-3, 20-dione, 9-flouro-11, 21-dihydroxy-16, 17-[(1-methylethylidene)bis(oxy)]-(11β16a). Its structural formula is:

structurestructure

Each gram of triamcinolone acetonide cream contains 1 mg triamcinolone acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION


Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. The
mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory
methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical
efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable
correlation exists between vasoconstrictor potency and therapeutic efficacy in man.
Pharmacokinetics -
The extent of percutaneous absorption of topical corticosteroids is determined by many factors
including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical
corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in
the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous
absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct
for treatment of resistant dermatoses (see DOSAGE AND ADMINISTRATION). Once absorbed
through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to
24 31 6
through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to
systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying
degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.
Some of the topical corticosteroids and their metabolites are also excreted into the bile.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Triamcinolone acetonide cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Triamcinolone acetonide cream is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.

Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.

Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.

Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (See PRECAUTIONS-PEDIATRIC USE).

If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

Information for the Patient

INFORMATION FOR PATIENTS SECTION

Patients using topical corticosteroids should receive the following information and instructions.

  1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
  2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed.
  3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.
  4. Patients should report any signs of local adverse reactions especially under occlusive dressing.
  5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.
Laboratory Tests

LABORATORY TESTS SECTION

The following tests may be helpful in evaluating the HPA axis suppression:

  • Urinary free cortisol test
  • ACTH stimulation test
Carcinogenesis, Mutagenesis, and Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.

Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.

Pregnancy Category C

PREGNANCY SECTION

Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are not adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.

Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushings's syndrome and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence:

  • Burning
  • Itching
  • Irritation
  • Dryness
  • Folliculitis
  • Hypertrichosis
  • Acneiform eruptions
  • Hypopigmentation
  • Perioral dermatitis
  • Allergic contact dermatitis
  • Maceration of the skin
  • Secondary infection
  • Skin Atrophy
  • Striae
  • Miliaria

DOSAGE AND ADMINISTRATION

OVERDOSAGE SECTION

Topical corticosteroids are generally applied to the affected area as a thin film from two to three times daily depending on the severity of the condition.

Occlusive dressing may be used for the management of psoriasis or recalcitrant conditions.

If an infection develops, the use of occlusive dressing should be discontinued and appropriate antimicrobial therapy instituted.

HOW SUPPLIED

HOW SUPPLIED SECTION

Triamcinolone acetonide cream USP 0.1% is supplied in

80 g tube NDC 45802-064-36

Store at 59-86°F.

CAUTION: FEDERAL LAW PROHIBITS DISPENSING WITHOUT PRESCRIPTION.

MEDLINE REMEDY PHYTOPLEX SKIN REPAIR- (Dimethicone 5.0%)

SPL UNCLASSIFIED SECTION

Drug Facts

Active ingredient

OTC - ACTIVE INGREDIENT SECTION

Dimethicone 5.0%

Purpose

OTC - PURPOSE SECTION

Skin Protectant

Uses

INDICATIONS & USAGE SECTION


■ Temporarily protects and helps relieve chapped or cracked skin
■ Beneficial for face, hands, body and legs.

Warnings

WARNINGS SECTION

For external use only

Do not use on ■ deep or puncture wounds ■ animal bites ■ serious burns

When using this product
avoid contact with eyes.


Stop use and ask a doctor if

condition worsens
symptoms last for more than 7 days or clear up and occur again within a few days


Keep out of reach of children.
If swallowed, get medical help or contact a Poison Control Center right away.

Directions

DOSAGE & ADMINISTRATION SECTION

■ apply cream liberally as needed

Other information

STORAGE AND HANDLING SECTION

■ protect from freezing ■ avoid excessive heat

Inactive ingredients

INACTIVE INGREDIENT SECTION


Purified Water, Cocos Nucifera (Coconut oil), Olea Europaea (Olive Oil ), Cetyl Alcohol, Glyceryl
stearate, Stearic Acid, Peg 100 stearate,Propanediol, Glycol Distearate,1,2- Hexanediol, Caprylyl
Glycol, Hydroyacetophenone, Citrus Paradisi (Grapefruit) Peel Oil, Citrus Sinensis (Orange) Peel Oil,
Citrus Reticulata (Tangerine) Peel Oil, Hexyldecanol, Bisabolol, Cetylhydroxyproline Palmitamide,
Brassica Campestris (Rapeseed) Sterols, Yeast Ferment Extract, Hydrolyzed Soy Protein, 7-
Dehydrocholestrol, Caprylic/Capric Triglcerides, Glycerin, Phospholipids, Tocopherol Acetate,
Algae Extract, Eugenia Caryophyllus (Clove) Flower Extract, Camellia Sinensis (Green Tea) Leaf
Extract, Isopropyl Myristate, Methyldihydrojasmonate, Ethylene Brassylate, Vanilla Planifolia Extract,
Carthamus Tinctorius (Safflower) Oleosomes, Manuka Honey, Cholecalciferol, Phytonadione, Jojoba
Esters, Zea Mays (Corn) Oil

Silicone Tape

SPL UNCLASSIFIED SECTION

Uses
• To be applied to wounds or scars as a protective silicone barrier.
• As a dressing for abrasions, surgical wounds, donor sites, lacerations, ulcers, skin tears, superficial partial thickness burns, venous leg ulcers.
• As a dressing/securement for IV related uses, pressure ulcers, skin care, and wound care

Precautions
• Do not use if you are allergic to silicone
• Keep out of reach of children

Directions for use
• Apply tape to wound or scar as needed or as directed by your physician.  Remove tape, wash area, and apply new tape at least every 24 hours.

TriHeal 80- carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Packaged For:

Forreal Pharmaceuticals LLC

Royal Oak, MI 48067

Question or Comments please call 877-367-3250

LabelLabel

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
81877-508-80EA - Each81877-508d0aa7b24-baba-46ba-bf5b-37bb9782447812021-09-07
45802-064-05GM - Gram45802-0648da11a92-dfb6-4fdd-8ccc-bdcc604a7b7412012-07-24
45802-064-35GM - Gram45802-064fe4e08df-c77c-4353-95c3-91eb2c0ef6f912012-07-24
45802-064-36GM - Gram45802-0646abacc99-e30f-4303-b54a-0d9295784de712012-07-24
53329-152-04GM - Gram53329-15239008f22-6a04-4e7c-95fb-7bc29f80f0f312018-04-19

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 2 · 50 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
81877-50881877-508-80
45802-064
53329-15253329-152-44

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 2 · 50 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 3 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A086413-001TRIAMCINOLONE ACETONIDETRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 1982
A086413-002TRIAMCINOLONE ACETONIDETRIAMCINOLONE ACETONIDE0.025%CREAM / TOPICALATApproved before 1982
A086413-003TRIAMCINOLONE ACETONIDETRIAMCINOLONE ACETONIDE0.1%CREAM / TOPICALATApproved before 1982

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 3 matching rows.

Application-product, TE code table
Application-productTE code
A086413-001AT
A086413-002AT
A086413-003AT

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 4 · 129 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A086413-001TRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 198284e616aacf4f…
2026-09-14 22:38:342026-08A086413-002TRIAMCINOLONE ACETONIDE0.025%CREAM / TOPICALATApproved before 198284e616aacf4f…
2026-09-14 22:38:342026-08A086413-003TRIAMCINOLONE ACETONIDE0.1%CREAM / TOPICALATApproved before 198284e616aacf4f…
2026-08-18 06:07:402026-07A086413-001TRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 1982caaa826d4ba7…
2026-08-18 06:07:402026-07A086413-002TRIAMCINOLONE ACETONIDE0.025%CREAM / TOPICALATApproved before 1982caaa826d4ba7…
2026-08-18 06:07:402026-07A086413-003TRIAMCINOLONE ACETONIDE0.1%CREAM / TOPICALATApproved before 1982caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A086413-001TRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 1982011fe1cb6892…
2026-02-19 14:30 UTC2026-02A086413-002TRIAMCINOLONE ACETONIDE0.025%CREAM / TOPICALATApproved before 1982011fe1cb6892…
2026-02-19 14:30 UTC2026-02A086413-003TRIAMCINOLONE ACETONIDE0.1%CREAM / TOPICALATApproved before 1982011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A086413-001TRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 198231067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A086413-002TRIAMCINOLONE ACETONIDE0.025%CREAM / TOPICALATApproved before 198231067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A086413-003TRIAMCINOLONE ACETONIDE0.1%CREAM / TOPICALATApproved before 198231067a03dcf5…
2025-08-23 18:47 UTC2025-08A086413-001TRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 19826a471c1ec25d…
2025-08-23 18:47 UTC2025-08A086413-002TRIAMCINOLONE ACETONIDE0.025%CREAM / TOPICALATApproved before 19826a471c1ec25d…
2025-08-23 18:47 UTC2025-08A086413-003TRIAMCINOLONE ACETONIDE0.1%CREAM / TOPICALATApproved before 19826a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A086413-001TRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 1982fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A086413-002TRIAMCINOLONE ACETONIDE0.025%CREAM / TOPICALATApproved before 1982fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A086413-003TRIAMCINOLONE ACETONIDE0.1%CREAM / TOPICALATApproved before 1982fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A086413-001TRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 1982b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A086413-002TRIAMCINOLONE ACETONIDE0.025%CREAM / TOPICALATApproved before 1982b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A086413-003TRIAMCINOLONE ACETONIDE0.1%CREAM / TOPICALATApproved before 1982b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A086413-001TRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 198203ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A086413-002TRIAMCINOLONE ACETONIDE0.025%CREAM / TOPICALATApproved before 198203ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A086413-003TRIAMCINOLONE ACETONIDE0.1%CREAM / TOPICALATApproved before 198203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A086413-001TRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 19822680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A086413-002TRIAMCINOLONE ACETONIDE0.025%CREAM / TOPICALATApproved before 19822680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A086413-003TRIAMCINOLONE ACETONIDE0.1%CREAM / TOPICALATApproved before 19822680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A086413-001TRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 19825bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A086413-002TRIAMCINOLONE ACETONIDE0.025%CREAM / TOPICALATApproved before 19825bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A086413-003TRIAMCINOLONE ACETONIDE0.1%CREAM / TOPICALATApproved before 19825bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A086413-001TRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 1982d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A086413-002TRIAMCINOLONE ACETONIDE0.025%CREAM / TOPICALATApproved before 1982d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A086413-003TRIAMCINOLONE ACETONIDE0.1%CREAM / TOPICALATApproved before 1982d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A086413-001TRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 1982d06236e962d9…
2024-10-29 15:01 UTC2024-10A086413-002TRIAMCINOLONE ACETONIDE0.025%CREAM / TOPICALATApproved before 1982d06236e962d9…
2024-10-29 15:01 UTC2024-10A086413-003TRIAMCINOLONE ACETONIDE0.1%CREAM / TOPICALATApproved before 1982d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A086413-001TRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 198279d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A086413-002TRIAMCINOLONE ACETONIDE0.025%CREAM / TOPICALATApproved before 198279d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A086413-003TRIAMCINOLONE ACETONIDE0.1%CREAM / TOPICALATApproved before 198279d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A086413-001TRIAMCINOLONE ACETONIDE0.5%CREAM / TOPICALATApproved before 1982301d65b070ca…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 4 · 129 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A086413-001AT184e616aacf4f…
2026-09-14 22:38:342026-08A086413-002AT184e616aacf4f…
2026-09-14 22:38:342026-08A086413-003AT184e616aacf4f…
2026-08-18 06:07:402026-07A086413-001AT1caaa826d4ba7…
2026-08-18 06:07:402026-07A086413-002AT1caaa826d4ba7…
2026-08-18 06:07:402026-07A086413-003AT1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A086413-001AT1011fe1cb6892…
2026-02-19 14:30 UTC2026-02A086413-002AT1011fe1cb6892…
2026-02-19 14:30 UTC2026-02A086413-003AT1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A086413-001AT131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A086413-002AT131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A086413-003AT131067a03dcf5…
2025-08-23 18:47 UTC2025-08A086413-001AT16a471c1ec25d…
2025-08-23 18:47 UTC2025-08A086413-002AT16a471c1ec25d…
2025-08-23 18:47 UTC2025-08A086413-003AT16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A086413-001AT1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A086413-002AT1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A086413-003AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A086413-001AT1b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A086413-002AT1b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A086413-003AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A086413-001AT103ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A086413-002AT103ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A086413-003AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A086413-001AT12680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A086413-002AT12680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A086413-003AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A086413-001AT15bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A086413-002AT15bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A086413-003AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A086413-001AT1d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A086413-002AT1d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A086413-003AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A086413-001AT1d06236e962d9…
2024-10-29 15:01 UTC2024-10A086413-002AT1d06236e962d9…
2024-10-29 15:01 UTC2024-10A086413-003AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A086413-001AT179d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A086413-002AT179d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A086413-003AT179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A086413-001AT1301d65b070ca…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Triamcinolone AcetonideTRIAMCINOLONE ACETONIDEPadagis Israel Pharmaceuticals Ltd5d2fe6c2-3856-47f6-843f-077b2e1080a02024-12-31Adverse reactionsExact identifier
ndc (product): 45802-064
4c55cca4-fcc8-4720-9faa-aba97e3b5c19c94f97ca-18be-d941-e053-2995a90a03ff2022-09-08Warnings, Adverse reactionsExact identifier
spl set id: c94f97ca-18be-d941-e053-2995a90a03ff

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.